18 min ago
Amgen To Present At The Oppenheimer 24th Annual Healthcare Conference
Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com , under Investors.
Thu Dec 05, 2013
Critical Alerts For Bank of America, UnitedHealth Group, Chevron,...
To see what our analysts have discovered about these stocks read the InvestorsObserver's PriceWatch Alerts at http://www.investorsobserver.com/pr/120420131 Today's PriceWatch Alerts cover the following stocks: Bank of America , UnitedHealth Group , Chevron , Amgen , and US Steel .
Wed Dec 04, 2013
Best Biotech CEO of 2013: Your Vote Counts
Stock performance has always been an important measuring stick for the Biotech CEO of the Year award.
Tue Dec 03, 2013
Cytokinetics' CEO Presents at Piper Jaffray Healthcare Conference
So we get started. Good morning, everyone. I want to welcome you to the 25th Annual Piper Jaffray and Companies Healthcare Conference.
Sat Nov 30, 2013
The Motley Fool
This Week in Biotech
With the SPDR S&P Biotech Index up 47% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Tue Nov 26, 2013
BioMarin: Where Biotech and Rodney Dangerfield Cross Paths
Last week an FDA panel all but guaranteed that Vimizim -- BioMarin Pharmaceutical's new drug for Morquio IV syndrome -- will be approved without any label restrictions.
Mon Nov 25, 2013
Wall St. Cheat Sheet
3 Monday Morning Biotech Movers
Although this is a holiday week, that hasn't stopped several biotech stocks from making headlines in the market.
FDA Approves Bayer HealthCare, Onyx Pharmaceuticals, Inc.'s...
U.S. FDA Approves NEXAVARA for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment WHIPPANY, N.J. /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary , today announced that the U.S. Food and Drug Administration has ... (more)
Fri Nov 22, 2013
U.S. FDA Approves NEXAVARA (sorafenib) for the Treatment of Patients ...
U.S. FDA Approves NEXAVARA for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment WHIPPANY, N.J., THOUSAND OAKS, Calif.
Celgene's Kyprolis Draws Focus Away From Amgen
Bank of America Merrill Lynch biotech analyst Rachel McMinn commented on how an increased focus on Celgene's Kyprolis Cardiovascular toxicities among centers have stolen the spotlight from Amgen .
Gabriel Vargas to Present at GTC's Neurological Biomarkers Mtg. on Mar 19-21, 2014 in San Diego
These include poor preclinical models, subjective rating scales and the lack in our understanding of pathophysiology for many of these disorders.
Wed Nov 20, 2013
Deutsche Bank Reiterates on Amgen Following Biosimilar Conference
In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Amgen , and raised the price target from $138.00 to $142.00.
Tue Nov 19, 2013
Applied Clinical Trials
Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study ...
These data from the first 52-week study of a PCSK9 inhibitor were presented for the first time today in a Clinical Science: Special Reports session at the American Heart Association Scientific Sessions 2013 in According to the Centers for Disease Control and Prevention, more than 71 million American adults have high LDL-C.2 Elevated LDL-C is ... (more)
Mon Nov 18, 2013
Amgen Presents Interim Overall Survival Data From Phase 3 Study Of...
Amgen today announced interim overall survival results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor .
YY Inc. (NASDAQ:YY) and Amgen Inc. (NASDAQ:AMGN) Added to Equity...
Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding YY Inc. and Amgen Inc. .
Amgen Given Buy Rating at TheStreet
The analysts wrote, "Amgen has been reiterated by TheStreet Ratings as a buy with a ratings score of A. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and reasonable valuation levels.
Fri Nov 15, 2013
Pacific Business Times
Thousand Oaks cancer drug firm raises $9M
Thousand Oaks-based ImmunGene, a cancer treatment firm led by a former Amgen scientist, has raised $9 million from Ally Bridge Group, an investment group with ties to Hong Kong.
Thu Nov 14, 2013
IPO Preview: Xencor
Based in Monrovia, CA, Xencor scheduled a $75 million IPO with a market capitalization of $325 million on the Nasdaq at a price range midpoint of $15 for Friday, November 15, 2013.
Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
Amgen will host a webcast investor meeting at the American Heart Association Scientific Sessions 2013 on Tuesday, Nov. 19, at 7 p.m. CST.
The Motley Fool
Better Buy: Biogen or Amgen?
The two drugs racked up sales of $733 million and $403 million, respectively, in the third quarter.